Market Cap ₹60892 Cr.
Stock P/E 50.7
P/B -
Current Price ₹28656.2
Book Value ₹ 0
Face Value 10
52W High ₹30499.9
Dividend Yield 1.43%
52W Low ₹ 22465.8
Abbott India Ltd is a healthcare company engaged in pharmaceuticals enterprise. The Company has a portfolio of technology-based offerings in diagnostics, medical devices, nutritional and branded well-known pharmaceuticals. Its commercial enterprise operations are divided into four commercial enterprise divisions: Women's Health & Gastrointestinal, Gastroenterology and Hepatic Care; Speciality Care; GenNext & Vaccines, and Consumer Care. Women's Health & Gastrointestinal, Gastroenterology and Hepatic Care division has a combination of internationaal and local brands present inside the pregnancy, constipation and liver diseases segments. The Speciality Care department includes various merchandise within the treatment of central nervous system and metabolic problems. The GenNext department focuses on several remedy areas, inclusive of pain management, nutrients and pregnancy. Its vaccines comprises Enteroshield (typhoid vaccine) and Rotasure (rotavirus diarrhea vaccine). The Consumer Care division is present inside the over-the-counter antacid segment.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | TTM |
|---|---|
| Net Sales | |
| Other Income | |
| Total Income | |
| Total Expenditure | |
| Operating Profit | |
| Interest | |
| Depreciation | |
| Exceptional Income / Expenses | |
| Profit Before Tax | |
| Provision for Tax | |
| Profit After Tax | |
| Adjustments | |
| Profit After Adjustments | |
| Adjusted Earnings Per Share |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 28% | 15% | 17% | 23% |
| ROE Average | NA% | NA% | NA% | NA% |
| ROCE Average | NA% | NA% | NA% | NA% |
| #(Fig in Cr.) |
|---|
| Shareholder's Funds |
| Minority's Interest |
| Borrowings |
| Other Non-Current Liabilities |
| Total Current Liabilities |
| Total Liabilities |
| Fixed Assets |
| Other Non-Current Assets |
| Total Current Assets |
| Total Assets |
| #(Fig in Cr.) |
|---|
| Opening Cash & Cash Equivalents |
| Cash Flow from Operating Activities |
| Cash Flow from Investing Activities |
| Cash Flow from Financing Activities |
| Net Cash Inflow / Outflow |
| Closing Cash & Cash Equivalent |
| # |
|---|
| Earnings Per Share (Rs) |
| CEPS(Rs) |
| DPS(Rs) |
| Book NAV/Share(Rs) |
| Core EBITDA Margin(%) |
| EBIT Margin(%) |
| Pre Tax Margin(%) |
| PAT Margin (%) |
| Cash Profit Margin (%) |
| ROA(%) |
| ROE(%) |
| ROCE(%) |
| Receivable days |
| Inventory Days |
| Payable days |
| PER(x) |
| Price/Book(x) |
| Dividend Yield(%) |
| EV/Net Sales(x) |
| EV/Core EBITDA(x) |
| Net Sales Growth(%) |
| EBIT Growth(%) |
| PAT Growth(%) |
| EPS Growth(%) |
| Debt/Equity(x) |
| Current Ratio(x) |
| Quick Ratio(x) |
| Interest Cover(x) |
| Total Debt/Mcap(x) |
| # | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 | 74.99 |
| FII | 0.2 | 0.2 | 0.2 | 0.19 | 0.19 | 0.18 | 0.18 | 0.18 | 0.18 | 0.16 |
| DII | 7.95 | 7.86 | 8.39 | 8.62 | 8.78 | 8.83 | 8.74 | 8.91 | 8.81 | 9 |
| Public | 16.86 | 16.95 | 16.42 | 16.21 | 16.05 | 16 | 16.1 | 15.93 | 16.02 | 15.85 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 | 1.59 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.17 | 0.17 | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |
| Public | 0.36 | 0.36 | 0.35 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 |
Pros
